Institutions / DAFNA Capital Management LLC / Activity
Activity — DAFNA Capital Management LLC
63 moves.
| Date | Action | Company | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|
| Q1 2026 as of | Trim | Cytokinetics Inc Common stock | $-10.12M | -154K -41.37% | 217,497 3.26% of portfolio | medium |
| Q1 2026 as of | Add | CMPS COMPASS Pathways plc ADR | $8.89M | +1.6M +198.24% | 2,418,882 3.04% of portfolio | medium |
| Q1 2026 as of | Trim | Axogen, Inc. Common stock | $-7.52M | -227K -47.58% | 249,960 1.88% of portfolio | medium |
| Q1 2026 as of | Add | Nektar Therapeutics Common stock | $6.49M | +90K +120.24% | 165,178 2.70% of portfolio | medium |
| Q1 2026 as of | Add | Larimar Therapeutics, Inc. Common stock | $4.91M | +1.1M +116.06% | 2,029,164 2.08% of portfolio | low |
| Q1 2026 as of | Exit | 04635X102 Common stock | $-3.99M | -305K -100.00% | 0 | low |
| Q1 2026 as of | Add | Bicara Therapeutics Inc. Common stock | $3.19M | +160K +61.22% | 421,733 1.91% of portfolio | low |
| Q1 2026 as of | Trim | Revolution Medicines, Inc. Common stock | $-2.32M | -24K -3.94% | 580,678 12.85% of portfolio | low |
| Q1 2026 as of | Trim | 78464A870 Common stock | $-2.30M | -18K -5.35% | 318,505 9.25% of portfolio | low |
| Q1 2026 as of | Trim | Xenon Pharmaceuticals Inc. Common stock | $-2.16M | -37K -12.91% | 250,772 3.32% of portfolio | low |
| Q1 2026 as of | Trim | KalVista Pharmaceuticals Inc Common stock | $-1.80M | -89K -25.06% | 267,402 1.22% of portfolio | low |
| Q1 2026 as of | New | Fulcrum Therapeutics, Inc. Common stock | $1.57M | +205K | 205,000 0.36% of portfolio | low |
| Q1 2026 as of | New | KIDS Orthopediatrics Corp Common Stock | $1.52M | +96K | 95,659 0.35% of portfolio | low |
| Q1 2026 as of | Trim | Edgewise Therapeutics, Inc. Common stock | $-1.50M | -48K -29.74% | 112,236 0.80% of portfolio | low |
| Q1 2026 as of | Trim | Syndax Pharmaceuticals Inc Common stock | $-1.41M | -61K -21.77% | 217,355 1.16% of portfolio | low |
| Q1 2026 as of | Trim | Ascendis Pharma A/S Common stock | $-1.14M | -5K -17.74% | 23,177 1.21% of portfolio | low |
| Q1 2026 as of | New | CytomX Therapeutics, Inc. Common stock | $1.08M | +230K | 230,000 0.25% of portfolio | low |
| Q1 2026 as of | New | Maze Therapeutics, Inc. Common stock | $1.04M | +35K | 35,000 0.24% of portfolio | low |
| Q1 2026 as of | Trim | 464287556 Common stock | $-1.01M | -6K -8.81% | 62,095 2.39% of portfolio | low |
| Q1 2026 as of | Trim | Ideaya Biosciences, Inc. Common stock | $-999.6K | -30K -5.92% | 476,740 3.61% of portfolio | low |
| Q1 2026 as of | New | SCYNEXIS, Inc. Common stock | $996.6K | +1.1M | 1,086,956 0.23% of portfolio | low |
| Q1 2026 as of | Exit | ERAS Erasca, Inc. Common Stock | $-946.5K | -254K -100.00% | 0 | low |
| Q1 2026 as of | Add | Ultragenyx Pharmaceutical Inc. Common stock | $944.8K | +45K +281.88% | 61,100 0.29% of portfolio | low |
| Q1 2026 as of | Trim | Biohaven Ltd. Common stock | $-926.4K | -110K -11.46% | 845,735 1.63% of portfolio | low |
| Q1 2026 as of | Trim | Annexon, Inc. Common stock | $-858.7K | -155K -56.82% | 117,812 0.15% of portfolio | low |
| Q1 2026 as of | Add | Insulet Corp Common stock | $839.4K | +4K +58.22% | 10,870 0.52% of portfolio | low |
| Q1 2026 as of | New | ZBIO Zenas BioPharma, Inc. Common Stock | $830.9K | +43K | 42,500 0.19% of portfolio | low |
| Q1 2026 as of | Trim | IPSC Century Therapeutics, Inc. Common Stock | $-811.9K | -359K -12.86% | 2,434,353 1.25% of portfolio | low |
| Q1 2026 as of | Add | Stoke Therapeutics, Inc. Common stock | $716.3K | +22K +20.21% | 130,875 0.97% of portfolio | low |
| Q1 2026 as of | New | N62509109 Common stock | $640.2K | +20K | 20,000 0.15% of portfolio | low |
| Q1 2026 as of | New | PLRX Pliant Therapeutics, Inc. Common Stock | $613.6K | +487K | 487,000 0.14% of portfolio | low |
| Q1 2026 as of | Add | NGNE Neurogene Inc. Common Stock | $577.8K | +29K +102.46% | 56,635 0.26% of portfolio | low |
| Q1 2026 as of | Add | MPLT Maplight Therapeutics Inc Common Stock | $553.8K | +27K +18.95% | 171,006 0.79% of portfolio | low |
| Q1 2026 as of | Add | Inspire Medical Systems, Inc. Common stock | $495.2K | +10K +111.63% | 18,200 0.21% of portfolio | low |
| Q1 2026 as of | Add | GPCR Structure Therapeutics Inc. ADR | $457.9K | +10K +25.68% | 46,500 0.51% of portfolio | low |
| Q1 2026 as of | Trim | Day One Biopharmaceuticals, Inc. Common stock | $-443.8K | -21K -2.07% | 978,463 4.77% of portfolio | low |
| Q1 2026 as of | Trim | ARS Pharmaceuticals, Inc. Common stock | $-407.8K | -51K -26.72% | 139,285 0.25% of portfolio | low |
| Q1 2026 as of | Trim | Oric Pharmaceuticals, Inc. Common stock | $-405.3K | -42K -30.01% | 98,724 0.22% of portfolio | low |
| Q1 2026 as of | New | IBIO iBio, Inc. Common Stock | $367.9K | +194K | 193,638 0.08% of portfolio | low |
| Q1 2026 as of | Trim | N44445109 Common stock | $-347.1K | -35K -13.51% | 225,860 0.51% of portfolio | low |
| Q1 2026 as of | Add | Alkermes plc. Common stock | $326.5K | +9K +7.09% | 139,482 1.12% of portfolio | low |
| Q1 2026 as of | Trim | M68830112 Common stock | $-309.4K | -19K -16.91% | 94,405 0.35% of portfolio | low |
| Q1 2026 as of | Add | MBX MBX Biosciences, Inc. Common Stock | $304.5K | +10K +6.17% | 175,465 1.19% of portfolio | low |
| Q1 2026 as of | Add | Arcus Biosciences, Inc. Common stock | $270.0K | +13K +2.90% | 443,829 2.18% of portfolio | low |
| Q1 2026 as of | Exit | Brainsway Ltd. Common stock | $-246.6K | -13K -100.00% | 0 | low |
| Q1 2026 as of | Add | Cybin Inc. Common stock | $208.0K | +43K +9.53% | 498,361 0.54% of portfolio | low |
| Q1 2026 as of | Add | Lexeo Therapeutics, Inc. Common stock | $207.8K | +36K +10.62% | 377,059 0.49% of portfolio | low |
| Q1 2026 as of | Trim | Align Technology, Inc. Common stock | $-171.4K | -1K -6.25% | 15,000 0.58% of portfolio | low |
| Q1 2026 as of | Add | enGene Therapeutics Inc. Common stock | $161.5K | +24K +14.49% | 187,353 0.29% of portfolio | low |
| Q1 2026 as of | Trim | 74319B502 Common stock | $-147.1K | -23K -7.95% | 263,005 0.39% of portfolio | low |